Biotechnology•Small Cap
Clear visual breakdown: for every ₹100 earned, see how much flows to salaries, operating costs, government taxes, EPS profit, and your share.
High profit margin business
Workforce salaries, engineers & talent
Annual profit generated per stock unit
Direct cash dividends & buybacks
Select or type any investment amount to see how much commercial activity and earnings your money commands in 3B BLACKBIO DX LTD..
3B Blackbio Dx Limited manufactures and sells molecular diagnostic kits in India. The company designs, develops, manufactures and commercializes qPCR assays, rapid diagnostic tests, NGS-based diagnostic kits, digital PCR assays, and nucleic acid extraction solutions for reliable testing of patient samples, as well as offers oncology and hematology, antimicrobial resistance, infectious diseases, human genetics, extraction, and rapid antigen kits under the TRUPCR, TRUNGS, and TRURAPID brand names; and technical support and training services. 3B Blackbio Dx Limited was incorporated in 1972 and is headquartered in Bhopal, India.
Comparing 3B BLACKBIO DX LTD. with leading competitors in Healthcare & Pharma (Indian Market)
| # | Company Name | CMP | 1D % | P/E | Market Cap | Div Yield | 1Y Return |
|---|---|---|---|---|---|---|---|
| 1 | ANTHEM BIOSCIENCES LTD(ANTHEM) | ₹915.55 | +0.22% | 84.8 | ₹51,594 Cr | 0.22% | +31.15% |
| 2 | DR AGARWALS HEALTH CARE L(AGARWALEYE) | ₹516.35 | +0.91% | 94.9 | ₹16,371 Cr | 0.00% | +1.58% |
| 3 | AKUMS DRUGS AND PHARMA L(AKUMS) | ₹734.95 | -1.30% | 30.5 | ₹11,252 Cr | 0.14% | +64.24% |
| 4 | ADVANCED ENZYME TECH LTD(ADVENZYMES) | ₹280.30 | -1.41% | 18.1 | ₹3,023 Cr | 0.48% | -8.41% |
| 5 | 3B BLACKBIO DX LTD.Current | ₹1,284.20 | -1.90% | 19.1 | ₹1,102 Cr | 0.39% | +13.99% |
| 6 | ANUH PHARMA LIMITED(ANUHPHR) | ₹81.55 | -0.74% | 18.4 | ₹817 Cr | 1.84% | -4.38% |
| 7 | AAREY DRUGS & PHARM LTD(AAREYDRUGS) | ₹107.72 | -1.52% | 72.3 | ₹343 Cr | 0.00% | +12.46% |
Quotes are delayed by at least 15 minutes. Financial metrics and disclosures are cross-referenced with periodic statutory disclosures from the National Stock Exchange of India (NSE) and BSE India. This content is provided strictly for educational and portfolio analytics purposes, and does not constitute investment advice or Buy/Sell recommendations.